Loading…
Fujian-based Chinese pharmaceutical maker, per its industry classification; specific product portfolio not independently confirmed.
Fujian-based Chinese pharmaceutical maker, per its industry classification; specific product portfolio not independently confirmed.
Moat: none
Headquarters: Fujian, China · Employees: 200
Size Fujian Haixi Pharmaceuticals (2637.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $1.53B, the 486th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$152.20 on 6 Nov 2026.
Performance Over six months the shares fell 41.0%, against -17.6% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 3rd lowest of 18 in its peer set.
Growth Revenue grew 24.8% over the last twelve months (peer median +22.1%); the operating margin is 33.0% (peer median -297.1%).
Valuation It trades at 48.2× forward earnings against a peer median of 15.7× (2nd most expensive of 6).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | n/a | HK$632M | HK$506M | HK$350M | HK$247M |
| Revenue growth | — | +25% | +45% | +42% | — |
| Gross profit | n/a | HK$527M | HK$415M | HK$291M | HK$200M |
| EBITDA | n/a | HK$217M | HK$149M | HK$136M | HK$96.5M |
| Net income | n/a | HK$192M | HK$148M | HK$130M | HK$80.2M |
| Free cash flow | n/a | HK$109M | -HK$30.4M | HK$85.6M | HK$45.3M |
| Capital expenditure | n/a | HK$48.7M | HK$194M | HK$65.7M | HK$36.9M |
| Total debt | n/a | HK$123M | HK$71.2M | HK$55.1M | HK$103M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 2637.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.7% | -8.1% | 6th highest of 21 |
| 6-month return | -41.0% | -17.6% | 3rd lowest of 18 |
| Distance from 52-week high | -49.7% | -43.6% | 7th lowest of 21 |
| Revenue growth (TTM) | +24.8% | +22.1% | 9th highest of 18 |
| Operating margin | 33.0% | -297.1% | 3rd highest of 18 |
| Forward P/E | 48.2× | 15.7× | 2nd most expensive of 6 |
| Net debt / EBITDA | -6.3× | 1.0× | least indebted of 4 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Fujian Haixi Pharmaceuticals 2637.HK | Hong Kong | $1.53B | -41% | +25% | 33% | 48.2× | n/a | n/a |
| Hugel 145020.KS | South Korea | $1.52B | -26% | +17% | 38% | 15.7× | -7.9% | +15.0% |
| ANI Pharmaceuticals ANIP | United States | $1.55B | -18% | +31% | 13% | 7.6× | -4.1% | +33.5% |
| uniQure QURE | United States | $1.51B | -22% | +30% | -1,093% | n/a | n/a | n/a |
| TLC BioSciences 7924.TWO | Taiwan | $1.57B | n/a | n/a | n/a | n/a | n/a | n/a |
| PELL Bio-Med Technology 6949.TW | Taiwan | $1.49B | +126% | +5% | -1,720% | n/a | n/a | n/a |
| Zhuhai Trinomab Pharmaceutical 688806.SS | China | $1.58B | n/a | +238% | -1,196% | n/a | n/a | n/a |
| Intellia Therapeutics NTLA | United States | $1.59B | -19% | +13% | -712% | n/a | n/a | n/a |
| Nuvation Bio NUVB | United States | $1.46B | -13% | +1,084% | -81% | n/a | n/a | n/a |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | United States | $1.60B | +5% | +20% | -5% | n/a | n/a | n/a |
| Precigen PGEN | United States | $1.60B | +6% | +1,875% | -46% | 6.9× | n/a | n/a |
| Tyra Bioscience TYRA | United States | $1.45B | -38% | n/a | n/a | n/a | n/a | n/a |
| Kardigan KARD | United States | $1.45B | n/a | n/a | n/a | n/a | n/a | n/a |
| PolyPeptide PPGN.SW | Switzerland | $1.62B | +6% | +22% | 7% | 51.3× | n/a | n/a |
| Wuhan Healthgen Biotechnology 688765.SS | China | $1.64B | -44% | +90% | -297% | n/a | n/a | n/a |
| Korsana Biosciences KRSA | United States | $1.41B | +43% | -13% | -359% | n/a | n/a | n/a |
| Taysha Gene Therapies TSHA | United States | $1.41B | -36% | -32% | -2,855% | n/a | n/a | n/a |
| Peptron 087010.KS | South Korea | $1.67B | -63% | +16% | -427% | n/a | n/a | n/a |
| Nurix Therapeutics NRIX | United States | $1.67B | -7% | +739% | 41% | n/a | -19.0% | +36.4% |
| Generate Biomedicines GENB | United States | $1.68B | -4% | +56% | -737% | n/a | n/a | n/a |
| Hualan Biological Vaccine 301207.SZ | China | $1.39B | -21% | -28% | -7% | 42.8× | 36.5% | -13.1% |